• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Ocular Therapeutix dips on big losses, missed projections

Ocular Therapeutix dips on big losses, missed projections

March 13, 2020 By Sean Whooley

Ocular Therapeutix logoOcular Therapeutix (NSDQ:OCUL) shares were marginally down today on fourth-quarter results that came up short the consensus forecast after massive losses.

The Bedford, Mass.-based ophthalmic insert maker posted losses of $26 million, or -53¢ per share, on sales of $2.3 million for the three months ended Dec. 31, 2019, for a 49.5% bottom-line slide despite nearly tripling the revenue made in the same quarter in 2018.

Adjusted to exclude one-time items, losses per share were -47¢, 2¢ behind Wall Street projections.

One of the largest differences between Q4 2019 and Q4 2018 came with the launch of the company’s Dextenza corticosteroid indicated for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix noted that its marketing expenses increased by nearly $5 million with the commercial launch of the product.

“Ocular Therapeutix has had an impressive final quarter of 2019 and strong start to 2020,” Ocular Therapeutix president & CEO Antony Mattessich said in a news release. “Key performance indicators on the launch of Dextenza point to a building momentum, most notably in the number of billable inserts ordered by ASC’s and hospitals that show a definitive acceleration.”

Ocular Therapeutix did not offer full-year guidance for the new fiscal year, but did say it expects net product revenue for Dextenza to range between $2.4 million and $2.6 million in the first quarter of 2020.

The Company anticipates net product revenue of Dextenza for the first quarter of 2020 will be in the range of $2.4 million to $2.6 million.

OCUL shares were down -0.8% at $4.25 per share in mid-morning trading today.

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup, Optical/Ophthalmic, Wall Street Beat Tagged With: Ocular Therapeutix

More recent news

  • Vicarious Surgical inks surgical robot collab with hospital, eyes first clinical patients
  • Bioliberty launches hub for soft-robotic wearable devices
  • Zynex submits laser pulse oximeter to FDA
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub
  • Product liability lawsuits target Medtronic, Boston Scientific spinal cord stim tech

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy